Canaccord Adams downgrades Poniard Pharmaceuticals (Nasdaq: PARD) from Buy to Hold, slashes price target to $2.50.

Canaccord analyst says, "Following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE